GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Withus Pharmaceutical Co Ltd (XKRX:330350) » Definitions » Research & Development

Withus Pharmaceutical Co (XKRX:330350) Research & Development : ₩2,297 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Withus Pharmaceutical Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Withus Pharmaceutical Co's Research & Development for the three months ended in Dec. 2024 was ₩426 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was ₩2,297 Mil.


Withus Pharmaceutical Co Research & Development Historical Data

The historical data trend for Withus Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Withus Pharmaceutical Co Research & Development Chart

Withus Pharmaceutical Co Annual Data
Trend Jun19 Jun20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial 1,512.39 1,420.15 2,356.73 1,868.17 2,296.78

Withus Pharmaceutical Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 320.47 429.19 1,080.92 361.15 425.52

Withus Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩2,297 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Withus Pharmaceutical Co  (XKRX:330350) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Withus Pharmaceutical Co Research & Development Related Terms

Thank you for viewing the detailed overview of Withus Pharmaceutical Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Withus Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
9 Dongsan-ro 12-gil, Seocho-gu, 3rd, 4th, and 5th Floors of Withers Building, Seoul, KOR
Withus Pharmaceutical Co Ltd is a pharmaceutical company. The firm is engaged in the manufacturing and selling of various medicines such as Broazette long-acting tablet, Wipina tablets, Mantini tablets, and Choline syrup among others.

Withus Pharmaceutical Co Headlines

No Headlines